Mineralys Therapeutics (MLYS) Operating Expenses (2022 - 2026)

Mineralys Therapeutics has disclosed Operating Expenses across 5 years of filings, most recently posting $45.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $45.3 million, up 2.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $171.5 million (down 14.88% YoY), and the FY2025 annual result was $170.6 million, down 11.33% from the prior year.
• Operating Expenses came in at $45.3 million for Q1 2026 at Mineralys Therapeutics, up from $38.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $60.1 million in Q3 2024 to a low of $6.5 million in Q2 2022.
• The 5-year median for Operating Expenses is $35.4 million (2024), against an average of $30.9 million.
• Across the five-year window, Operating Expenses jumped 253.94% in 2023 and tumbled 31.57% in 2025, its largest moves.
• Mineralys Therapeutics' Operating Expenses stood at $10.0 million in 2022, then soared by 176.89% to $27.7 million in 2023, then surged by 86.81% to $51.8 million in 2024, then decreased by 26.05% to $38.3 million in 2025, then grew by 18.44% to $45.3 million in 2026.
• The last three Operating Expenses figures came in at $45.3 million (Q1 2026), $38.3 million (Q4 2025), and $41.1 million (Q3 2025), per Business Quant data.